References
- Heppner DG Jr., Kester KE, Ockenhouse CF, et al. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine. 2005;23(17–18):2243–2250.
- Agnandji ST, Lell B, Soulanoudjingar SS, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. New Engl J Med. 2011;365(20): 1863–1875.
- Aide P, Dobano C, Sacarlal J, et al. Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial. Vaccine. 2011;29(35):6059–6067.
- Mian-McCarthy S, Agnandji ST, Lell B, et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. New Engl J Med. 2012;367(24):2284–2295.
- Doll TAPF, Raman S, Dey R, et al. Nanoscale assemblies and their biomedical applications. J R Soc Interface. 2013;10(80). Article ID 20120740.
- Langer R. Drug delivery and targeting. Nature. 1998;392(6679):5–10.
- Latham T, Galarza JM. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J Virol. 2001;75(13):6154–6165.
- Kaba SA, Brando C, Guo Q, et al. A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. J Immunol. 2009;183(11):7268–7277.
- Kaba SA, McCoy ME, Doll TA, et al. Protective antibody and CD8+ T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine. PLoS One. 2012;7(10):e48304.
- Chai SK, Clavijo P, Tam JP, et al. Immunogenic properties of multiple antigen peptide systems containing defined T-epitpoe and B-epitope. J Immunol. 1992;149(7):2385–2390.
- Mahajan B, Berzofsky JA, Boykins RA, et al. Multiple antigen peptide vaccines against Plasmodium falciparum malaria. Infect Immun. 2010;78(11):4613–4624.
- Seder RA, Chang LJ, Enama ME, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013;341(6152):1359–1365.
- Raman S, Machaidze G, Lustig A, et al. Structure-based design of peptides that self-assemble into regular polyhedral nanoparticles. Nanomedicine. 2006;2(2):95–102.
- Pimentel TAPF, Yan Z, Jeffers SA, et al. Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine. Chem Biol Drug Des. 2009;73(1):53–61.
- Babapoor S, Neef T, Mittleholzer C, et al. A novel vaccine using nanoparticle platform to present immunogenic M2e against avian influenza infection. Influenza Res Treat. 2011. Article ID 126794.
- Wahome N, Pfeiffer T, Ambiel I, et al. Conformation-specific display of 4E10 and 2F5 epitopes on self-assembling protein nanoparticles as a potential HIV vaccine. Chem Biol Drug Des. 2012;80(3):349–357.
- El Bissati K, Zhou Y, Dasgupta D, et al. Effectiveness of a novel immunogenic nanoparticle platform for toxoplasma peptide vaccine in HLA transgenic mice. Vaccine. 2014;32(26):3243–3248.
- Schroeder U, Graff A, Buchmeier S, et al. Peptide nanoparticles serve as a powerful platform for the immunogenic display of poorly antigenic actin determinants. J Mol Biol. 2009;386(5):1368–1381.
- McCoy ME, Golden HE, Doll TAPF, et al. Mechanisms of protective immune responses induced by the Plasmodium falciparum CSP-based self-assembling protein nanoparticle vaccine. Malar J. 2013;12(1):136.
- Yang Y, Burkhard P. Encapsulation of gold nanoparticles into self-assembling protein nanoparticles. J Nanobiotechnol. 2012;10(1):42.